202 related articles for article (PubMed ID: 22278196)
1. Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).
Fujiki A; Imamura T; Furutani A; Hatano W; Asai D; Hirashima Y; Miyachi M; Tamura S; Tsuchiya K; Iehara T; Ishida H; Yoshihara T; Hosoi H
J Pediatr Hematol Oncol; 2012 Jul; 34(5):402-5. PubMed ID: 22278196
[TBL] [Abstract][Full Text] [Related]
2. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications.
Schmidt HH; Strehl S; Thaler D; Strunk D; Sill H; Linkesch W; Jäger U; Sperr W; Greinix HT; König M; Emberger W; Haas OA
Leukemia; 2004 Jun; 18(6):1115-21. PubMed ID: 15085163
[TBL] [Abstract][Full Text] [Related]
3. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
[TBL] [Abstract][Full Text] [Related]
4. RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13).
Panagopoulos I; Isaksson M; Lindvall C; Björkholm M; Ahlgren T; Fioretos T; Heim S; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2000 Aug; 28(4):415-24. PubMed ID: 10862050
[TBL] [Abstract][Full Text] [Related]
5. Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation.
Rozman M; Camós M; Colomer D; Villamor N; Esteve J; Costa D; Carrió A; Aymerich M; Aguilar JL; Domingo A; Solé F; Gomis F; Florensa L; Montserrat E; Campo E
Genes Chromosomes Cancer; 2004 Jun; 40(2):140-5. PubMed ID: 15101047
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related acute myeloid leukaemia with t(8;16)(p11;p13);MOZ-CBP and polymorphisms in detoxifying and DNA repair genes.
Boyd EM; Bench AJ; Vaghela KJ; Campbell GN; Chowdhury FB; Gudgin EJ; Scott MA; Erber WN
Leukemia; 2009 Jun; 23(6):1164-7. PubMed ID: 19158836
[No Abstract] [Full Text] [Related]
9. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
10. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia.
Daifu T; Kato I; Kozuki K; Umeda K; Hiramatsu H; Watanabe K; Kamiya I; Taki T; Nakahata T; Heike T; Adachi S
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e325-7. PubMed ID: 24390445
[TBL] [Abstract][Full Text] [Related]
12. RT-PCR analysis of acute myeloid leukemia with t(8;16)(p11;p13): identification of a novel MOZ/CBP transcript and absence of CBP/MOZ expression.
Panagopoulos I; Fioretos T; Isaksson M; Mitelman F; Johansson B; Theorin N; Juliusson G
Genes Chromosomes Cancer; 2002 Dec; 35(4):372-4. PubMed ID: 12378533
[No Abstract] [Full Text] [Related]
13. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
[TBL] [Abstract][Full Text] [Related]
14. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
15. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8)(p23;p11).
Imamura T; Kakazu N; Hibi S; Morimoto A; Fukushima Y; Ijuin I; Hada S; Kitabayashi I; Abe T; Imashuku S
Genes Chromosomes Cancer; 2003 Apr; 36(4):413-9. PubMed ID: 12619166
[TBL] [Abstract][Full Text] [Related]
16. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
Scholl C; Breitinger H; Schlenk RF; Döhner H; Fröhling S; Döhner K;
Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
[TBL] [Abstract][Full Text] [Related]
18. [Disappearance of residual disease confirmed by RT-PCR following induction chemotherapy in two hypoplastic leukemia patients with t(8;21)].
Sawada M; Tsurumi H; Yamada T; Hara T; Oyama M; Moriwaki H
Rinsho Ketsueki; 1999 Apr; 40(4):311-7. PubMed ID: 10355140
[TBL] [Abstract][Full Text] [Related]
19. Genomic characterization of MOZ/CBP and CBP/MOZ chimeras in acute myeloid leukemia suggests the involvement of a damage-repair mechanism in the origin of the t(8;16)(p11;p13).
Panagopoulos I; Isaksson M; Lindvall C; Hagemeijer A; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2003 Jan; 36(1):90-8. PubMed ID: 12461753
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
